Cargando…

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation

Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activation is broadly used and continually improved. However, a subset of patients eventually progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkens, Lina, Sailer, Verena, Lessel, Davor, Janzen, Ella, Greimeier, Sarah, Kirfel, Jutta, Perner, Sven, Pantel, Klaus, Werner, Stefan, von Amsberg, Gunhild
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808994/
https://www.ncbi.nlm.nih.gov/pubmed/35109899
http://dx.doi.org/10.1186/s13046-022-02255-y
_version_ 1784643930003865600
author Merkens, Lina
Sailer, Verena
Lessel, Davor
Janzen, Ella
Greimeier, Sarah
Kirfel, Jutta
Perner, Sven
Pantel, Klaus
Werner, Stefan
von Amsberg, Gunhild
author_facet Merkens, Lina
Sailer, Verena
Lessel, Davor
Janzen, Ella
Greimeier, Sarah
Kirfel, Jutta
Perner, Sven
Pantel, Klaus
Werner, Stefan
von Amsberg, Gunhild
author_sort Merkens, Lina
collection PubMed
description Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activation is broadly used and continually improved. However, a subset of patients eventually progresses to castration-resistant disease. To date, various mechanisms of resistance have been identified including the development of AR-independent aggressive variant prostate cancer based on neuroendocrine transdifferentiation (NED). Here, we review the highly complex processes contributing to NED. Genetic, epigenetic, transcriptional aberrations and posttranscriptional modifications are highlighted and the potential interplay of the different factors is discussed. Background Aggressive variant prostate cancer (AVPC) with traits of neuroendocrine differentiation emerges in a rising number of patients in recent years. Among others, advanced therapies targeting the androgen receptor axis have been considered causative for this development. Cell growth of AVPC often occurs completely independent of the androgen receptor signal transduction pathway and cells have mostly lost the typical cellular features of prostate adenocarcinoma. This complicates both diagnosis and treatment of this very aggressive disease. We believe that a deeper understanding of the complex molecular pathological mechanisms contributing to transdifferentiation will help to improve diagnostic procedures and develop effective treatment strategies. Indeed, in recent years, many scientists have made important contributions to unravel possible causes and mechanisms in the context of neuroendocrine transdifferentiation. However, the complexity of the diverse molecular pathways has not been captured completely, yet. This narrative review comprehensively highlights the individual steps of neuroendocrine transdifferentiation and makes an important contribution in bringing together the results found so far.
format Online
Article
Text
id pubmed-8808994
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88089942022-02-03 Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation Merkens, Lina Sailer, Verena Lessel, Davor Janzen, Ella Greimeier, Sarah Kirfel, Jutta Perner, Sven Pantel, Klaus Werner, Stefan von Amsberg, Gunhild J Exp Clin Cancer Res Review Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activation is broadly used and continually improved. However, a subset of patients eventually progresses to castration-resistant disease. To date, various mechanisms of resistance have been identified including the development of AR-independent aggressive variant prostate cancer based on neuroendocrine transdifferentiation (NED). Here, we review the highly complex processes contributing to NED. Genetic, epigenetic, transcriptional aberrations and posttranscriptional modifications are highlighted and the potential interplay of the different factors is discussed. Background Aggressive variant prostate cancer (AVPC) with traits of neuroendocrine differentiation emerges in a rising number of patients in recent years. Among others, advanced therapies targeting the androgen receptor axis have been considered causative for this development. Cell growth of AVPC often occurs completely independent of the androgen receptor signal transduction pathway and cells have mostly lost the typical cellular features of prostate adenocarcinoma. This complicates both diagnosis and treatment of this very aggressive disease. We believe that a deeper understanding of the complex molecular pathological mechanisms contributing to transdifferentiation will help to improve diagnostic procedures and develop effective treatment strategies. Indeed, in recent years, many scientists have made important contributions to unravel possible causes and mechanisms in the context of neuroendocrine transdifferentiation. However, the complexity of the diverse molecular pathways has not been captured completely, yet. This narrative review comprehensively highlights the individual steps of neuroendocrine transdifferentiation and makes an important contribution in bringing together the results found so far. BioMed Central 2022-02-02 /pmc/articles/PMC8808994/ /pubmed/35109899 http://dx.doi.org/10.1186/s13046-022-02255-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Merkens, Lina
Sailer, Verena
Lessel, Davor
Janzen, Ella
Greimeier, Sarah
Kirfel, Jutta
Perner, Sven
Pantel, Klaus
Werner, Stefan
von Amsberg, Gunhild
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
title Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
title_full Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
title_fullStr Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
title_full_unstemmed Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
title_short Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
title_sort aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808994/
https://www.ncbi.nlm.nih.gov/pubmed/35109899
http://dx.doi.org/10.1186/s13046-022-02255-y
work_keys_str_mv AT merkenslina aggressivevariantsofprostatecancerunderlyingmechanismsofneuroendocrinetransdifferentiation
AT sailerverena aggressivevariantsofprostatecancerunderlyingmechanismsofneuroendocrinetransdifferentiation
AT lesseldavor aggressivevariantsofprostatecancerunderlyingmechanismsofneuroendocrinetransdifferentiation
AT janzenella aggressivevariantsofprostatecancerunderlyingmechanismsofneuroendocrinetransdifferentiation
AT greimeiersarah aggressivevariantsofprostatecancerunderlyingmechanismsofneuroendocrinetransdifferentiation
AT kirfeljutta aggressivevariantsofprostatecancerunderlyingmechanismsofneuroendocrinetransdifferentiation
AT pernersven aggressivevariantsofprostatecancerunderlyingmechanismsofneuroendocrinetransdifferentiation
AT pantelklaus aggressivevariantsofprostatecancerunderlyingmechanismsofneuroendocrinetransdifferentiation
AT wernerstefan aggressivevariantsofprostatecancerunderlyingmechanismsofneuroendocrinetransdifferentiation
AT vonamsberggunhild aggressivevariantsofprostatecancerunderlyingmechanismsofneuroendocrinetransdifferentiation